AstraZeneca posts Q3 earnings beat and multiple oncology trial wins
AstraZeneca PLC reported third‑quarter revenue of $16.21 billion, beating estimates, and core earnings per share of $2.79. The company also highlighted several late‑stage oncology trial successes and reaffirmed its mid‑to‑high‑single‑digit revenue growth and low‑double‑digit EPS growth outlook. The results lifted the stock about 6.8% as institutional buying accelerated.
Why it matters
The earnings beat and reaffirmed guidance suggest the company will continue to deliver revenue and earnings growth, supporting the current valuation multiples (≈24 × earnings). Analysts note that the strong oncology pipeline and healthy margins underpin the upside potential for investors.
Key facts
- 1Q3 revenue was $16.21 billion, ahead of the $16 billion estimate. timothysykes.com
- 2Core EPS for Q3 was $2.79. timothysykes.com
- 3EBIT margin for the quarter was 23.3%. timothysykes.com
- 4Gross margin was 81.9%. timothysykes.com
- 5Full‑year revenue to date is about $58.7 billion. timothysykes.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.